Structure and Properties of Bioactive Glass-Modified Calcium Phosphate/Calcium Sulfate Biphasic Porous Self-Curing Bone Repair Materials and Preliminary Research on Their Osteogenic Effect
Overview
Affiliations
In this study, calcium phosphate (CP)/calcium sulfate biphasic bone repair materials were modified with bioactive-glass (BG) to construct a self-curing bone repair material. Tetracalcium phosphate, calcium hydrogen phosphate dihydrate, and calcium sulfate hemihydrate (CSH) with different BG ratios and phosphate solution were reacted to prepare a porous self-curing bone repair material (CP/CSH/BG). The solidification time was about 12 min, and the material was morphologically stable in 24 h. The porosity was about 50%, with a pore size around 200 μm. The strength of CP/CSH/BG was approaching trabecular bone, and could be gradually degraded in Tris-HCl solution. MC3T3-E1 cells were cultured in the leaching solution of the materials. Cytotoxicity was detected using Cell Counting Kit 8 assays, and the expression of osteogenesis-related biomarkers was detected using quantitative real-time reverse transcription PCR (qRT-PCR). The results showed that all BG groups had increased ALP and ARS staining, implying that the BG groups could promote osteoblast mineralization in vitro. qRT-PCR showed significant upregulation of bone-related gene expression (Osx, Ocn, Runx2, and Col1) in the 20% BG group (p < 0.05). Therefore, the CP/CSH/BG self-curing bone repair materials can promote osteogenesis, and might be applied for bone regeneration, especially for polymorphic bone defect repair.
Current and Future Perspectives of Bioactive Glasses as Injectable Material.
Mirt A, Ficai D, Oprea O, Vasilievici G, Ficai A Nanomaterials (Basel). 2024; 14(14).
PMID: 39057873 PMC: 11280465. DOI: 10.3390/nano14141196.
Limitations and modifications in the clinical application of calcium sulfate.
Lun D, Li S, Li N, Mou L, Li H, Zhu W Front Surg. 2024; 11:1278421.
PMID: 38486794 PMC: 10937423. DOI: 10.3389/fsurg.2024.1278421.
Liu S, Chen J, Huang S, Lin S, Chen W Pharmaceuticals (Basel). 2023; 16(5).
PMID: 37242463 PMC: 10222783. DOI: 10.3390/ph16050680.